FDA Approves Acalabrutinib with Venetoclax for CLL or SLL By Ogkologos - March 4, 2026 138 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AMPLIFY study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Highlights the Importance of a Strong EU Commitment Towards Robust Science and Innovation Policies Following Meeting of EU Research Ministers on 29 May... Metastatic Breast Cancer: ESMO Clinical Practice Guideline EMA Recommends Extending Indications for Decitabine / Cedazuridine MOST POPULAR Characterisation of KRAS, Including KRAS G12C, Mutations in Gastrointestinal and Metastatic... July 2, 2021 EMA Recommends Granting a Marketing Authorisation for Ivosidenib March 1, 2023 FDA Approves Liquid Biopsy NGS Companion Diagnostic Test for Multiple Cancers... November 10, 2020 EMA Recommends Granting a Marketing Authorisation for Nivolumab / Relatlimab August 11, 2022 Load more HOT NEWS What to Know About Peer-Reviewed Cancer Information and Its Role in... New Approach Uses Much Less Tissue to Analyze Tumor Proteins and... Why it’s difficult to estimate the number of extra cancer deaths... Approximately 1 Million of New Maternal Orphans Due to Cancer in...
